Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting
Isabelle Ray‐Coquard(Centre Léon Bérard), Jan Heidrich(Universidad de Granada), Jalid Sehouli(Charité - Universitätsmedizin Berlin), Ladislav Dušek(Institute of Health Information and Statistics), Nadya Dimitrova(Istituto Superiore di Sanità), Margit Mägi(Universidad de Granada), Christina Fotopoulou(Ovarian Cancer Action), Alice Nennecke, Gunnar B. Kristensen(Oslo University Hospital), Frédéric Amant(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Mario Šekerija(London Cancer), Marc Maynadié(Universidad de Granada), G. Schubert-Fritschle(Ludwig-Maximilians-Universität München), Pascale Grosclaude(Seoul National University Children's Hospital), Florence Molinié, Annalisa Trama(Fondazione IRCCS Istituto Nazionale dei Tumori), Ignace Vergote(KU Leuven), Alain Monnereau, Domenica Lorusso(Agostino Gemelli University Polyclinic), Patricia Pautier(Université Paris-Saclay), Maarit K. Leinonen(University of Helsinki), Éric Pujade-Lauraine(Eau de Paris (France)), Véronique Bouvier(Inserm), Anne‐Marie Bouvier(Inserm), Jonathan A. Ledermann(London Cancer), Xavier Troussard(Centre Hospitalier Universitaire de Caen Normandie), Nea Malila(Istituto Superiore di Sanità), Erik Rokkones(Oslo University Hospital), Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Marc Colonna, Henrik Falconer(Karolinska University Hospital), Anne‐Valérie Guizard, B. Lapôtre‐Ledoux(Fondazione IRCCS Istituto Nazionale dei Tumori), Monika Hackl(Universidad de Granada), Anne-Sophie Woronoff, Roland Stabenow(Fondazione IRCCS Istituto Nazionale dei Tumori), P. Arveux(Istituto Superiore di Sanità), Jutta Engel, MJ Seckl(Imperial College Healthcare NHS Trust), Sabine Luttmann(Fondazione IRCCS Istituto Nazionale dei Tumori), L.F.A.G. Massuger(Radboud University Nijmegen), Michel Velten(Pancreatic Cancer Action Network), Kris Henau, E. Van Eycken(Istituto Superiore di Sanità), Brigitte Trétarre(Queen's University Belfast), M. Robaszkiewicz(University of Milan), Claire Schvartz(Fondazione IRCCS Istituto Nazionale dei Tumori), Isabelle Baldi(Pancreatic Cancer Action Network), Simona Bara, Giorgia Mangili(Vita-Salute San Raffaele University)
Cited by 34
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k